ArticleJournal of virology2026
ALDH1L1 suppresses the replication of porcine epidemic diarrhea virus by degrading viral nucleocapsid and envelope proteins.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- PEDV envelope protein promotes viral replication by remodeling host iron homeostasis via the TRIM28-KLF15-FPN axis.Journal of virology · 2026Article
- The Interplay Between Autophagy and Porcine Epidemic Diarrhea Virus: From Molecular Mechanisms to Therapeutic Perspectives.Microorganisms · 2026Review
- PABPC1 Restricts Bat-Origin Swine Acute Diarrhea Syndrome Coronavirus Infection via TOLLIP-Mediated Degradation of Viral Nucleocapsid Protein.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Porcine epidemic diarrhea virus (PEDV) is a highly pathogenic alphacoronavirus that causes severe diarrhea. It has a high fatality rate among newborn piglets, posing a considerable economic burden to the swine industry. Therefore, elucidating the host-pathogen interaction is warranted to advance precision antiviral therapies. Herein, for the first time, we noted a marked upregulation of aldehyde dehydrogenase 1 family member L1 (ALDH1L1) during PEDV infection. Furthermore, ALDH1L1 exerts its antiviral effects by specifically binding to the viral nucleocapsid (N) and envelope (E) proteins and mediating their degradation via the autophagosome-lysosomal degradation pathway. Additional experiments revealed that this degradation process is mediated via the interactions of ALDH1L1 with the E3 ubiquitin ligase STUB1 and the cargo receptor TOLLIP, eliminating the N and E structural glycoproteins via the autophagolysosomal pathway. Our study findings suggest the ALDH1L1-STUB1-TOLLIP axis as a novel antiviral target and propose a new strategy for viral clearance based on the degradation of host protein. Furthermore, our research provides valuable information on how host antiviral factors impede PEDV replication as a regulator of the protein degradation pathway.IMPORTANCEPorcine epidemic diarrhea virus (PEDV) is a highly pathogenic alphacoronavirus that causes fatal hemorrhagic gastroenteritis among neonatal piglets. This causes significant financial losses. During infection, certain host factors can activate the innate immune regulatory network to antagonize the viral replication cycle, interfere with the virus invasion, inhibit virus replication, prevent virus assembly and release, and enhance the host's immune response. Our study revealed that the host metabolic enzyme ALDH1L1 acts as a novel antiviral restriction factor that mediates the autophagy-lysosome-targeted degradation of viral structural proteins (N/E) via the STUB1 (E3 ubiquitin ligase)-TOLLIP (autophagy adaptor protein) axis. Our study findings offer new perspectives on the mechanism by which host antiviral factors inhibit PEDV by regulating the protein degradation pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.